Gildeuretinol acetate clinical trials
Also written C20-D3-Retinyl Acetate and ALK-001.
How each study uses gildeuretinol acetate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the gildeuretinol acetate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2019 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Alkeus Pharmaceuticals, Inc. (5)
Studies
Open first, then newest update. How each study uses gildeuretinol acetate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study of ALK-001 on the Progression of Stargardt DiseaseRecruitingPhase 3Alkeus Pharmaceuticals, Inc.NCT07419334Written as ALK-001
- Phase 2 Tolerability and Effects of ALK-001 on Stargardt DiseaseActive, not recruitingPhase 2Alkeus Pharmaceuticals, Inc.NCT02402660Written as ALK-001
- Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)Active, not recruitingPhase 2Alkeus Pharmaceuticals, Inc.NCT04239625Written as ALK-001
- Phase 2/3 Study of ALK-001 in Geographic AtrophyCompletedPhase 2/3Alkeus Pharmaceuticals, Inc.NCT03845582Written as ALK-001 oral capsule
- Phase 1 Safety Study of ALK-001 in Healthy VolunteersCompletedPhase 1Alkeus Pharmaceuticals, Inc.NCT02230228Written as ALK-001 (No generic name)
Codes
What other systems call gildeuretinol acetate · ClinicalTrials.gg INT016967
- UNII (FDA) JN7W3M3OI7GILDEURETINOL ACETATEOne source FDA
- NCI Thesaurus C203240Gildeuretinol AcetateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JN7W3M3OI7 | GILDEURETINOL ACETATE | One source FDA |
| NCI Thesaurus | C203240 | Gildeuretinol Acetate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.